View all cases
- Case details
- Status—ActionProcedural applicationCategoryCase management orders
- Parties
- Respondents
- Abbott Logistics B.V.Operating co.
- Abbott Diagnostics GmbHOperating co.
- Abbott FranceOperating co.
- Abbott OyOperating co.
- Abbott Diabetes Care Inc.Operating co.
- Newyu, Inc.Other / unknown
- Abbott LaboratoriesOperating co.
- Abbott Laboratories A/SOperating co.
- Abbott Scandinavia AktiebolagOperating co.
- AbbottOperating co.
- Abbott GmbHOperating co.
- Abbott Gesellschaft m.b.H.Operating co.
- Abbott s.r.l.Operating co.
- Abbott B.V.Operating co.
Representatives- Christian Dekoninck-Taylor Wessing
- François Pochart-August Debouzy
- Division
- Paris LD
- Judges
- Technology
- Electrical engineeringDigital communication
- InstrumentsMedical technology
- Language
- —
- First decided
- Oct 11, 2024
How this compares
How long the court takes to reach a first decision.
| Median days to first decision | |
|---|---|
| All UPC | 124 |
| Paris LD | Locked |
| Judge Camille Lignières | Locked |
At the UPC: Dexcom Group (39 cases)·Abbott Group (67 cases)
Start 14-day free trialAlready a user? Sign in
Related cases
All proceedings on this patentThis dispute contains 4 other proceedings
UPC CoA 840/2024·UPC CFI 625/2024·CC 14065/2024·UPC CFI 395/2023
Decisions
- 2024-10-11Amend DocumentPublic
Summary: Paris Local Division dismissed Abbott's application under Rule 263 RoP for leave to amend its defence/case to include the newly released LibreLinkUp app version 4.12.0, in DexCom's infringement action concerning EP 3 831 282. While the first condition (amendment could not have been made earlier) was met, the second condition was not: granting the amendment would unreasonably hinder DexCom's preparation for the oral hearing scheduled in 10 days. Abbott retains the option to bring a separate action for non-infringement regarding the new product.
Show the legal issues (4)
- Leave to amend case under Rule 263 RoP
- Timing of amendment in relation to oral hearing
- Unreasonable hindrance of the opposing party
- Commercial sensitivity of new product launch
Documents
- EB70144B9D8B046FF2434042B06CE689_en.pdf2024-10-11EN